CDXI - Cardax, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.1000
-0.0200 (-16.67%)
At close: 3:55PM EDT
Stock chart is not supported by your current browser
Previous Close0.1200
Open0.1200
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0720 - 0.1470
52 Week Range0.0720 - 0.2500
Volume355,813
Avg. Volume21,854
Market Cap13.602M
Beta (3Y Monthly)-0.37
PE Ratio (TTM)N/A
EPS (TTM)-0.0320
Earnings DateNov 12, 2018 - Nov 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.00
Trade prices are not sourced from all markets
  • PR Newswirelast month

    Cardax Reports Q1 2019 Results

    HONOLULU, May 17, 2019 /PRNewswire/ -- Cardax, Inc. (CDXI) announced results for the quarter ended March 31, 2019, in its Quarterly Report on Form 10-Q filed May 15, 2019 with the SEC. Cardax continued to make progress in Q1 2019 across its primary areas of focus: the ZanthoSyn® consumer health business, CHASE human clinical trial, and Rx development programs. Q1 2019 represented the top performing quarter, as measured in dollars and units, for retail sales of ZanthoSyn® to customers at General Nutrition Corporation ("GNC") stores ("sell-through") since ZanthoSyn®'s launch at GNC in Q1 2017.

  • PR Newswire3 months ago

    Cardax Reports 2018 Results

    HONOLULU, March 28, 2019 /PRNewswire/ -- Cardax, Inc. (CDXI) announced results for the year ended December 31, 2018, in its Annual Report on Form 10-K filed today with the SEC. The increase in revenues primarily reflects the strong sell-through of ZanthoSyn® in General Nutrition Corporation ("GNC") stores in Hawaii as well as in California, Nevada, and New York where the Company has focused its sales and marketing efforts to date. The Company plans to expand its sales and marketing efforts to other major markets in 2019 as resources permit.

  • PR Newswire5 months ago

    Cardax to Present at NobleCon XV

    LEADING SMALL CAP/MICRO CAP CONFERENCE FEATURES 600 ATTENDEES HONOLULU , Jan. 25, 2019 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI), a life sciences company focused on inflammatory health, today announced ...

  • PR Newswire7 months ago

    Cardax and GNC Announce Expanded ZanthoSyn® Sales and Marketing Program

    HONOLULU, Dec. 3, 2018 /PRNewswire/ -- Cardax, Inc. (CDXI) and GNC (GNC) announced today that they are expanding the sales and marketing program for ZanthoSyn®, Cardax's premium astaxanthin dietary supplement for inflammatory health and longevity. GNC is the exclusive brick-and-mortar retail channel for ZanthoSyn®.

  • PR Newswire7 months ago

    Cardax Names Former Amarin Head of Development Paresh N. Soni, MD, PhD, to lead Clinical and Regulatory Strategy

    HONOLULU, Nov. 28, 2018 /PRNewswire/ -- Cardax, Inc. (CDXI) announced that Paresh N. Soni, M.D., Ph.D., the former Senior Vice President and Head of Development for Amarin Corporation, will join Cardax as Chief Clinical and Regulatory Strategist and as a member of the Company's Scientific Advisory Board. Dr. Soni will guide clinical and regulatory strategy for Cardax's pharmaceutical platform, interact with the FDA, and advise the Company on a full range of development issues.

  • PR Newswire7 months ago

    Cardax Reports Q3 2018 Results

    HONOLULU, Nov. 13, 2018 /PRNewswire/ -- Cardax, Inc. (CDXI) announced its results for the third quarter of 2018. Revenues from sales of ZanthoSyn®, its premium astaxanthin dietary supplement for inflammatory health and longevity, increased 102% from $272,049 in Q2 2018 to $549,540 in Q3 2018. Q3 2017 had the largest ZanthoSyn® revenues in 2017, primarily reflecting the first nationwide stocking orders from GNC, the Company's exclusive U.S. "brick-and-mortar" retail channel.

  • PR Newswire9 months ago

    Cardax Launches Human Clinical Trial Targeting Cardiovascular Inflammatory Health

    HONOLULU, Oct. 2, 2018 /PRNewswire/ -- Cardax, Inc. (CDXI) has launched its Cardiovascular Health Astaxanthin Supplement Evaluation (CHASE) clinical trial targeting cardiovascular inflammatory health. The randomized, double-blind, placebo-controlled CHASE clinical trial will evaluate the effect of low-dose and high-dose ZanthoSyn®, Cardax's premium astaxanthin supplement, on cardiovascular health, as measured by C-Reactive Protein (CRP) levels, over 12 weeks in up to 360 subjects with documented cardiovascular risk factors.

  • PR Newswire10 months ago

    Cardax Reports Q2 2018 Results

    HONOLULU, Aug. 13, 2018 /PRNewswire/ -- Cardax, Inc. (CDXI) today announced its results for the second quarter of 2018. Revenues from sales of ZanthoSyn®, its premium astaxanthin dietary supplement for inflammatory health and longevity, increased more than four times, to $272,049 in Q2 2018 from $66,237 in Q2 2017. The results primarily reflect sales to GNC driven by the strong sell-through rate of ZanthoSyn® in Hawaii as well as an accelerating sales trend in California, Nevada, and New York.

  • PR Newswire11 months ago

    Cardax Announces Successful Completion of Warrant Exchange Offer

    HONOLULU, July 30, 2018 /PRNewswire/ -- Cardax, Inc. (CDXI) announced today that it successfully closed its warrant exchange offer ("Exchange Offer") on Friday, July 27, 2018, at 5:00 p.m., Eastern Daylight Time. The Exchange Offer allowed holders of Cardax $0.625 warrants expiring in February 2019 to exchange those warrants, together with a payment of $0.15 per share, for registered shares of the Company's common stock. 9.6 million warrants were exchanged pursuant to the Exchange Offer and resulted in gross proceeds to the Company of $1.44 million.

  • PR Newswire11 months ago

    Cardax Announces Extension of Warrant Exchange Offer to July 27, 2018

    HONOLULU, July 23, 2018 /PRNewswire/ -- Cardax, Inc. (CDXI) announced today that it is extending to July 27, 2018, the period for its offer ("Exchange Offer") to allow holders of warrants for its common stock that have an exercise price of $0.625 and expire in February 2019 ("Warrants") to exchange those Warrants, together with a payment of $0.15 per share, for registered shares of the Cardax's common stock ("Shares"). The Exchange Offer was scheduled to expire at 5:00 p.m., New York City time, on July 23, 2018, unless extended by Cardax. The extended expiration date for the Exchange Offer is 5:00 p.m., New York City time, on July 27, 2018.

  • PR Newswirelast year

    Cardax Announces Effectiveness of Registration Statement and Commencement of Warrant Exchange Offer

    HONOLULU, June 22, 2018 /PRNewswire/ -- Cardax, Inc. (CDXI) announced today that the Securities and Exchange Commission has declared effective the Company's Registration Statement on Form S-4 in connection with a one-time offer to allow holders of its $0.625 warrants expiring in February 2019 to exchange those warrants, together with a payment of $0.15 per share, for registered shares of the Company's common stock. This exchange offer is available to original holders and anyone that acquires these warrants. The exchange offer commenced today, June 22, 2018, and will expire at 5:00 p.m., New York City time, on July 23, 2018, unless extended by the Company.